Pediatric Clinics of North America - CIPERJ

More documents

Recommendations

Info

VENOUS THROMBOEMBOLISM IN CHILDREN 321 [30] Ettingshausen CE, Veldmann A, Beeg T, et al. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost 1999;25:537–41. [31] Rivard GE, David M, Farrell C, et al. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 1995;126(4):646–52. [32] Konkle BA, Bauer KA, Weinstein R, et al. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion 2003;43:390–4. [33] Zaunschirm A, Muntean W. Correction of hemostatic imbalances induced by L-asparaginase therapy in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1986; 3:19–25. [34] Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving L-asparaginase for acute lymphoblastic leukemia. Results of the PARKAA study. Thromb Haemost 2003;90: 235–44. [35] Haussmann U, Fischer J, Eber S, et al. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combin antithrombin III/defibrotide therapy. Haematologica 2006;91:795–800. [36] Meister B, Kropshofer G, Klein-Franke A, et al. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of thrombosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2008;50(2):298–303. [37] Cahn MD, Rohrer MJ, Martella MB, et al. Long-term follow-up of Greenfield inferior vena cava filter placement in children. J Vasc Surg 2001;34:820–5. [38] Goldenberg NA. Long-term outcomes of venous thrombosis in children. Curr Opin Hematol 2005;12:370–6. [39] van Ommen CH, Heijboer H, van den Dool EJ, et al. Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome. J Thromb Haemost 2003;1:2516–22. [40] Bick RL. Prothrombin G20210A mutation, antithombin, heparin cofactor II, protein C, and protein S defects. Hematol Oncol Clin North Am 2003;17:9–36. [41] Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1–7. [42] Nowak-Göttl U, Junker R, Kruez W, et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001;97:858–62. [43] Massicotte P, Julian JA, Gent M, et al. An open label randomized controlled trial of low molecular weight heparin compared to heparin and Coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003;109: 85–92. [44] Oren H, Devecioglu O, Ertem M, et al. Analysis of pediatric thrombotic patients in Turkey. Pediatr Hematol Oncol 2004;21:573–83. [45] Nowak-Göttl U, Von Kries R, Gobel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed 1997;76:F163–7. [46] Michaels LA, Gurian M, Hagyi T, et al. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant. Pediatrics 2004;114:703–7. [47] Massicotte MP, Dix D, Monagle P, et al. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr 1998;133:770–6. [48] Mocan H, Beattie TJ, Murphy AV, et al. Renal venous thrombosis in infancy: long-term follow-up. Pediatr Nephrol 1991;5:45–9. [49] Nuss R, Hays T, Manco-Johnson M. Efficacy and safety of heparin anticoagulation for neonatal renal vein thrombosis. Am J Pediatr Hematol Oncol 1994;16:127–31. [50] Keidan I, Lotan D, Gazit G, et al. Early neonatal renal venous thrombosis: long-term outcome. Acta Paediatr 1994;83:1225–7.
322 GOLDENBERG & BERNARD [51] Kuhle S, Massicotte P, Chan A, et al. A case series of 72 neonates with renal vein thrombosis: data from the 1-800-NO-CLOTS Registry. Thromb Haemost 2004;92:929–33. [52] Kosch A, Kuwertz-Broking E, Heller C, et al. Renal venous thrombosis in neonates: prothrombotic risk factors and long-term follow-up. Blood 2004;104:1356–60. [53] deVeber G, Andrew M, Adams C, et al. Cerebral sinovenous thrombosis in children. N Engl J Med 2001;345:417–23. [54] deVeber GA, MacGregor D, Curtis R, et al. Neurologic outcome in survivors of childhood arterial ischemic stroke and sinovenous thrombosis. J Child Neurol 2000;15:316–24. [55] Kenet G, Waldman D, Lubetsky A, et al. Paediatric cerebral sinus vein thrombosis. Thromb Haemost 2004;92:713–8. [56] De Schryver EL, Blom I, Braun KP, et al. Long-term prognosis of cerebral venous sinus thrombosis in childhood. Dev Med Child Neurol 2004;46:514–9. [57] Gurakan F, Eren M, Kocak N, et al. Extrahepatic portal vein thrombosis in children: etiology and long-term follow-up. J Clin Gastroenterol 2004;38:368–72. [58] Meissner MH, Manzo RA, Bergelin RO, et al. Deep venous insufficiency: the relationship between lysis and subsequent reflux. J Vasc Surg 1993;18:596–605. [59] Kahn SR, Dsmarais S, Ducruet T, et al. Comparison of the Villalta and Ginsberg clinical scales to diagnose the post-thrombotic syndrome: correlation with patient-reported disease burden and venous valvular reflux. J Thromb Haemost 2006;4:907–8. [60] Revel-Vilk S, Sharathkumar A, Massicotte P, et al. Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: a longitudinal study by ultrasound. J Thromb Haemost 2004;2:42–6. [61] Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457–62. [62] Palareti G, Legnani C, Cosmi B, et al. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002;87:7–12. [63] Eichinger S, Minar E, Bialonczyk C, et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003;290:1071–4.
Page 2 and 3: Pediatr Clin N Am 55 (2008) xiii-xi
Page 4 and 5: Pediatr Clin N Am 55 (2008) 287-304
Page 6 and 7: DECISION ANALYSIS IN PEDIATRIC HEMA
Page 16 and 17: Nietert et al [30] Treatment of sic
Page 24 and 25: VENOUS THROMBOEMBOLISM IN CHILDREN
Page 42 and 43: PEDIATRIC ARTERIAL ISCHEMIC STROKE
Page 58 and 59: CARE OF PATIENTS WITH VASCULAR ANOM
Page 74 and 75: 358 RODRIGUEZ & HOOTS Fig. 1. X-lin
Page 76 and 77: Table 1 Clotting factor concentrate
Page 78 and 79: Table 1 (continued ) Factor VIII (o
Page 80 and 81: 364 RODRIGUEZ & HOOTS was administe
Page 82 and 83: 366 RODRIGUEZ & HOOTS Antifibrinoly
Page 84 and 85: 368 RODRIGUEZ & HOOTS infections an
Page 86 and 87: 370 RODRIGUEZ & HOOTS Fig. 3. Schem
Page 88 and 89:
372 RODRIGUEZ & HOOTS protein is no
Page 90 and 91:
374 RODRIGUEZ & HOOTS [2] Berntorp
Page 92 and 93:
376 RODRIGUEZ & HOOTS [42] Carcao M
Page 94 and 95:
378 ROBERTSON et al von Willebrand
Page 96 and 97:
380 ROBERTSON et al Fig. 2. A propo
Page 98 and 99:
382 ROBERTSON et al a heterogenous
Page 100 and 101:
384 ROBERTSON et al of considering
Page 102 and 103:
386 ROBERTSON et al Type 2M Type 2M
Page 104 and 105:
388 ROBERTSON et al Desmopressin is
Page 106 and 107:
390 ROBERTSON et al References [1]
Page 108 and 109:
392 ROBERTSON et al [46] Nesbitt IM
Page 110 and 111:
394 BLANCHETTE & BOLTON-MAGGS A key
Page 112 and 113:
396 BLANCHETTE & BOLTON-MAGGS recep
Page 114 and 115:
398 BLANCHETTE & BOLTON-MAGGS and p
Page 116 and 117:
400 BLANCHETTE & BOLTON-MAGGS Fig.
Page 118 and 119:
402 BLANCHETTE & BOLTON-MAGGS in di
Page 120 and 121:
404 BLANCHETTE & BOLTON-MAGGS the s
Page 122 and 123:
406 BLANCHETTE & BOLTON-MAGGS findi
Page 124 and 125:
408 BLANCHETTE & BOLTON-MAGGS as a
Page 126 and 127:
410 BLANCHETTE & BOLTON-MAGGS splen
Page 128 and 129:
412 BLANCHETTE & BOLTON-MAGGS with
Page 130 and 131:
414 BLANCHETTE & BOLTON-MAGGS react
Page 132 and 133:
416 BLANCHETTE & BOLTON-MAGGS [16]
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
422 FASANO & LUBAN of storage and t
Page 140 and 141:
424 FASANO & LUBAN Leukocyte reduct
Page 142 and 143:
426 FASANO & LUBAN RBCs is decrease
Page 144 and 145:
Table 1 Blood component characteris
Page 146 and 147:
430 FASANO & LUBAN Alloimmunization
Page 148 and 149:
432 FASANO & LUBAN of individual un
Page 150 and 151:
434 FASANO & LUBAN patients have an
Page 152 and 153:
436 FASANO & LUBAN adults; therefor
Page 154 and 155:
438 FASANO & LUBAN [21]. Meta-analy
Page 156 and 157:
440 FASANO & LUBAN Pretransfusion m
Page 158 and 159:
442 FASANO & LUBAN [55,56]. This is
Page 160 and 161:
444 FASANO & LUBAN [20] Roseff SD,
Page 162 and 163:
Pediatr Clin N Am 55 (2008) 447-460
Page 164 and 165:
THALASSEMIA UPDATE 449 hypochromia
Page 166 and 167:
THALASSEMIA UPDATE 451 Fig. 1. Chan
Page 168 and 169:
THALASSEMIA UPDATE 453 delivery of
Page 170 and 171:
THALASSEMIA UPDATE 455 thromboses i
Page 172 and 173:
THALASSEMIA UPDATE 457 On the basis
Page 174 and 175:
THALASSEMIA UPDATE 459 [31] Kan YW,
Page 176 and 177:
Page 178 and 179:
ORAL IRON CHELATORS 463 large iron-
Page 180 and 181:
ORAL IRON CHELATORS 465 of 50 child
Page 182 and 183:
ORAL IRON CHELATORS 467 Table 2 Com
Page 184 and 185:
ORAL IRON CHELATORS 469 use in Nort
Page 186 and 187:
ORAL IRON CHELATORS 471 needed to d
Page 188 and 189:
ORAL IRON CHELATORS 473 in liver fi
Page 190 and 191:
ORAL IRON CHELATORS 475 in the lowe
Page 192 and 193:
ORAL IRON CHELATORS 477 Other oral
Page 194 and 195:
ORAL IRON CHELATORS 479 [12] Borgna
Page 196 and 197:
ORAL IRON CHELATORS 481 [55] Wonke
Page 198 and 199:
Page 200 and 201:
HYDROXYUREA FOR CHILDREN WITH SICKL
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Fig. 1. Guideline for initiating, m
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
504 TRACY & RICE congenital spheroc
Page 220 and 221:
506 TRACY & RICE and antibodies aga
Page 222 and 223:
508 TRACY & RICE limited splenic vo
Page 224 and 225:
510 TRACY & RICE constitutes the pi
Page 226 and 227:
512 TRACY & RICE German experience
Page 228 and 229:
514 TRACY & RICE Table 1 Effect of
Page 230 and 231:
516 TRACY & RICE decreased bilirubi
Page 232 and 233:
518 TRACY & RICE [13] Bader-Meunier
show all

Pediatric Clinics of North America - CIPERJ

Create successful ePaper yourself

Delete template?

Save as template?